IP Library Granted Patent US 10,327,946
Granted Patent B2
US 10,327,946 · App. 14/977,048 · Granted Jun 25, 2019

Intraocular delivery of bioactive molecules using iontophoresis

Inventors: Diogo de Sousa Martins (Sao Paulo, BR); Pierre Roy (Paris, FR); Giovanni Cavallo (Rome, IT); Fulvio Foschini (Rome, IT)
Assignee: KEMIN INDUSTRIES, INC.
A61F9/0026A61F9/0008A61K9/0009A61K9/0051A61K9/127A61K31/045A61K31/047A61K31/065A61P27/00A61P43/00A61N1/044A61N1/303
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,327,946
App. No.
14/977,048
Granted
Jun 25, 2019
Kind
B2
Abstract

Iontophoresis, a minimally-invasive methodology that uses a weak electric current to enhance penetration of ionized molecules into tissues, was found to be an effective technique for the intraocular delivery of large bioactive molecules, specifically lutein.

Claims (3)

1. A method of depositing at least one carotenoid in ocular tissues, comprising the steps of formulating a liposome having a positive zeta potential containing the at least one carotenoid in an amount effective to increase macular pigment in the ocular tissues of a subject, charging an iontophoresis device with a composition of the liposome containing at least one carotenoid, applying the iontophoresis device to the eye of the subject, and operating the iontophoresis device, wherein the at least one carotenoid is selected from the group consisting of lutein and zeaxanthin.

2. A method of treating or ameliorating age-related macular degeneration, comprising the steps of formulating a liposome having a positive zeta potential containing at least one carotenoid in an amount effective to increase macular pigment in the ocular tissues of a subject, charging an iontophoresis device with a composition of the liposome, applying the iontophoresis device to the eye of a subject, and operating the iontophoresis device, wherein the at least one carotenoid is selected from the group consisting of lutein and zeaxanthin.

3. The method of claim 2 , wherein treating or ameliorating age-related macular degeneration is preventing or delaying the progression of age-related macular degeneration.

Assignments (5)
GRANT OF PATENT SECURITY INTEREST Recorded Jul 12, 2021
From: KEMIN INDUSTRIES, INC.; KEMIN HOLDINGS, L.C.; KEMIN FOODS, L.C.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 056832/0569 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2016
From: CAVALLO, GIOVANNI
To: KEMIN INDUSTRIES, INC.
Reel/Frame 037723/0232 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2016
From: ROY, PIERRE
To: KEMIN INDUSTRIES, INC.
Reel/Frame 037723/0291 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2016
From: SOUSA MARTINS, DIOGO DE
To: KEMIN INDUSTRIES, INC
Reel/Frame 037723/0367 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2016
From: FOSCHINI, FULVIO
To: KEMIN INDUSTRIES, INC
Reel/Frame 037723/0418 →
Continuity (2)
Provisional Application 62094663 · Dec 19, 2014
Related Publication 20160175148A1 · Jun 23, 2016